Actively Recruiting
A Phase 1 Study of Navlimetostat Tablet Formulations
Led by Bristol-Myers Squibb · Updated on 2026-05-14
64
Participants Needed
3
Research Sites
24 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female
CONDITIONS
Official Title
A Phase 1 Study of Navlimetostat Tablet Formulations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adult female participants not of childbearing potential with no significant clinical findings
- Body mass index (BMI) between 18.0 and 35.0 kg/m2
- Adequate kidney and liver function as assessed by laboratory tests, including eGFR 60 90 mL/min/1.73m2 and liver enzymes 64 1.5 times the upper limit of normal
You will not qualify if you...
- Presence of any significant acute or chronic medical illness
- Current or recent gastrointestinal disease within 3 months that may affect drug absorption or metabolism
- Other protocol-specific exclusion criteria as defined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
CenExel iResearch - Decatur
Decatur, Georgia, United States, 30030
Actively Recruiting
2
Local Institution - 0003
Decatur, Georgia, United States, 30030
Not Yet Recruiting
3
PPD
Austin, Texas, United States, 78744
Actively Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here